Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.71 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.71 |
| ▸ | AKR1C3 | P42330 | 7/20 | 0.68 |
| ▸ | AKR1C2 | P52895 | 7/20 | 0.68 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.68 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.68 |
| ▸ | TSHR | P16473 | 2/20 | 0.68 |
| ▸ | CDC42 | P60953 | 1/20 | 0.68 |
| ▸ | RAC1 | P63000 | 1/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.58 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL506523 | 1.00 | TDP1 (0.71) | TDP1L3MBTL1AKR1C3AKR1C2PTGS2 | |
| SCHEMBL31619540 | 1.00 | TDP1 (0.71) | TDP1L3MBTL1AKR1C3AKR1C2PTGS2 | |
| SCHEMBL221436 | 0.90 | TDP1 (0.71) | TDP1L3MBTL1AKR1C3AKR1C2PTGS2 | |
| SCHEMBL1246306 | 0.88 | TDP1 (0.68) | TDP1L3MBTL1AKR1C3AKR1C2PTGS2 | |
| SCHEMBL27746752 | 0.88 | TDP1 (0.68) | TDP1L3MBTL1AKR1C3AKR1C2PTGS2 | |
| SCHEMBL13063821 | 0.88 | TDP1 (0.71) | TDP1L3MBTL1AKR1C3AKR1C2PTGS2 | |
| SCHEMBL9289868 | 0.87 | PTGS2 (0.66) | TDP1L3MBTL1AKR1C3AKR1C2PTGS2 | |
| SCHEMBL9239307 | 0.87 | PTGS2 (0.66) | TDP1L3MBTL1AKR1C3AKR1C2PTGS2 | |
| SCHEMBL29156025 | 0.87 | TDP1 (0.69) | TDP1L3MBTL1AKR1C3AKR1C2PTGS2 | |
| SCHEMBL21340468 | 0.87 | TDP1 (0.69) | TDP1L3MBTL1AKR1C3AKR1C2PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110841071-B | Poly (beta-amino ester) drug delivery system loaded with bioactive substances and preparation method thereof | 南通大学 | 2023-03-31 | — | — | CN | claimed |
| CN-109464670-B | Key amino acid site for regulating and controlling nucleoprotein nuclear production of influenza A virus and influenza B virus and application of key amino acid site as anti-influenza virus drug target | 中国科学院微生物研究所 | 2022-08-02 | — | — | CN | claimed |
| US-20200297798-A1 | KEY AMINO ACID SITES REGULATING NUCLEAR EXPORT OF NUCLEOPROTEIN IN INFLUENZA A AND B VIRUSES AND USE THEREOF AS ANTI-INFLUENZA VIRUS DRUG TARGETS | INSTITUTE OF MICROBIOLOGY, CHINESE ACADEMY OF SCIENCES (CN) | 2020-09-24 | — | — | US | claimed |
| CN-105908373-A | Cellulose acetate nanometer electrospun fiber membrane preparation method for releasing prodrug like Naproxen esters | 浙江浪莎内衣有限公司 | 2016-08-31 | — | — | CN | claimed |
| US-5912164-A | TREATING ENANTIOMERS WITH ENZYME TO ENRICH SOLUTION FOR CARBOXYLIC ACID OR ALCOHOL; EFFICIENT PRODUCTION OF ANTIINFLAMMATORY AGENTS USING BIOCATALYST | LABORATORIOS MENARINI S.A. (ES) | 1999-06-15 | — | — | US | claimed |
| EP-0687305-B1 | ESTERASE AND ITS USE IN BIOTRANSFORMATION | CHIROSCIENCE LTD (GB) | 1997-12-29 | — | — | EP | claimed |
| EP-0687305-A1 | ESTERASE AND ITS USE IN BIOTRANSFORMATION | Chiroscience Limited (GB) | 1995-12-20 | — | — | EP | claimed |
| WO-1994020634-A1 | ESTERASE AND ITS USE IN BIOTRANSFORMATION | CHIROSCIENCE LIMITED (GB) | 1994-09-15 | — | — | WO | claimed |
| CN-110841071-B | Poly (beta-amino ester) drug delivery system loaded with bioactive substances and preparation method thereof | 南通大学 | 2023-03-31 | — | — | CN | disclosed |
| EP-3737663-B1 | MANGANESE-CATALYSED HYDROGENATION OF ESTERS | UNIV COURT UNIV ST ANDREWS (GB) | 2023-02-22 | — | — | EP | disclosed |
| CN-109464670-B | Key amino acid site for regulating and controlling nucleoprotein nuclear production of influenza A virus and influenza B virus and application of key amino acid site as anti-influenza virus drug target | 中国科学院微生物研究所 | 2022-08-02 | — | — | CN | disclosed |
| US-20210053932-A1 | MANGANESE-CATALYSED HYDROGENATION OF ESTERS | UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS (GB) | 2021-02-25 | — | — | US | disclosed |
| US-20200297798-A1 | KEY AMINO ACID SITES REGULATING NUCLEAR EXPORT OF NUCLEOPROTEIN IN INFLUENZA A AND B VIRUSES AND USE THEREOF AS ANTI-INFLUENZA VIRUS DRUG TARGETS | INSTITUTE OF MICROBIOLOGY, CHINESE ACADEMY OF SCIENCES (CN) | 2020-09-24 | — | — | US | disclosed |
| CN-109464670-A | Regulation A type and Type B influenza nucleoprotein go out the key amino acid site of core and its purposes as anti-influenza virus medicament target spot | 中国科学院微生物研究所 | 2019-03-15 | — | — | CN | disclosed |
| EP-0414247-A2 | Cloning, expression and sequencing of an ester hydrolase genein escherichia coli | SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) | 1991-02-27 | — | — | EP | disclosed |
| US-4912254-A | Preparation of α-arylalkanoic acids | SYNTEX PHARMACEUTICAL INTERNATIONAL LIMITED (BM) | 1990-03-27 | — | — | US | disclosed |
| EP-0081993-B1 | OPTICALLY ACTIVE ALPHA-SUBSTITUTED ARYL KETONES, THEIR PREPARATION AND THEIR USE IN PREPARING ALPHA-ARYLALKANOIC ACIDS | SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) | 1988-08-17 | — | — | EP | disclosed |
| US-4749804-A | Preparation of stereoisomers of ketals | SYNTEX (U.S.A.) INC. (US) | 1988-06-07 | — | — | US | disclosed |
| US-4605758-A | Preparation of α-arylalkanoic acids | SYNTEX PHARMACEUTICALS INTERNATIONAL LTD. (BM) | 1986-08-12 | — | — | US | disclosed |
| EP-0081993-A2 | Optically active alpha-substituted aryl ketones, their preparation and their use in preparing alpha-arylalkanoic acids | SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) | 1983-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210053932-A1 | MANGANESE-CATALYSED HYDROGENATION OF ESTERS | ADH5, HDHD5, ADH1A | TDP1 3371/4885L3MBTL1 2046/4885AKR1C3 1642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.